[{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/nutrition.ts","type":"changed","fields":[{"field":"tldr","before":"\"Fifteen melanoma patients whose immunotherapy had failed received a stool transplant from someone whose immunotherapy had worked, then restarted the drug. Six benefited, including three lasting responses.\"","after":"\"Fifteen melanoma patients whose immunotherapy had failed received a stool transplant from someone whose immunotherapy had worked, then restarted the drug. Six of them benefited, including three with lasting responses.\""}]},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","commit":"dd90cde211","date":"2026-09-08","author":"Jude Gomila","message":"Diet, exercise and lifestyle front content","file":"src/data/nutrition.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"nct"},{"field":"phase"},{"field":"status"},{"field":"yearReported"},{"field":"enrolled"},{"field":"sponsor"},{"field":"setting"},{"field":"tldr"},{"field":"summary"},{"field":"result"},{"field":"outcomes"},{"field":"replication"},{"field":"cancers"},{"field":"drugs"},{"field":"technologies"},{"field":"terms"},{"field":"pathways"},{"field":"sections"},{"field":"bottlenecks"},{"field":"related"},{"field":"links"}]}]